ceftobiprole medocaril + vancomycin+aztreonam
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Bacterial Skin and Skin Structure Infections
Conditions
Acute Bacterial Skin and Skin Structure Infections
Trial Timeline
Feb 19, 2018 → Apr 22, 2019
NCT ID
NCT03137173About ceftobiprole medocaril + vancomycin+aztreonam
ceftobiprole medocaril + vancomycin+aztreonam is a phase 3 stage product being developed by Basilea Pharmaceutica for Acute Bacterial Skin and Skin Structure Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03137173. Target conditions include Acute Bacterial Skin and Skin Structure Infections.
What happened to similar drugs?
20 of 20 similar drugs in Acute Bacterial Skin and Skin Structure Infections were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03137173 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Bacterial Skin and Skin Structure Infections